会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • CELLULAR STANDARDS FOR GLYCATED HEMOGLOBIN AlC DETERMINATION
    • 用于糖化HEMOGLOBIN AlC测定的细胞标准品
    • WO2006110339A1
    • 2006-10-19
    • PCT/US2006/011884
    • 2006-03-30
    • STRECK LABORATORIES, INC.RYAN, WayneWU, Jiong
    • RYAN, WayneWU, Jiong
    • G01N33/72C07K14/805
    • G01N33/723Y10T436/10Y10T436/105831Y10T436/108331Y10T436/25Y10T436/25125
    • Disclosed are cellular hemoglobin AIc (Hb AIc ) normal and abnormal (high) controls for use in detecting Hb AIc levels. The present invention also relates to methods for generating cellular Hb AIc controls using red blood cells and methods for using the cellular controls. The present invention encompasses several methods for the preparation of Hb AIc cellular controls including: (1) a boronate method where the glycation occurs non-specif ically; (2) a stabilized diabetic blood method where the glycation occurs specifically on Hb AIc, and (3) the glycation of normal blood method that is achieved by controlling conditions such that glycation occurs predominantly on Hb AIc. These methods produce cellular Hb AIc controls with desirable stability and that can be detected on a variety of instruments. In preferred embodiments, the control contains intact erythrocytes .
    • 公开了用于检测Hb AIc水平的细胞血红蛋白AIc(Hb AIc)正常和异常(高)对照。 本发明还涉及使用红细胞产生细胞Hb AIc对照的方法和使用细胞对照的方法。 本发明包括几种用于制备HbA1c细胞对照的方法,包括:(1)硼酸盐法,其中糖化发生非特异性; (2)稳定的糖尿病血液法,其中糖化特异性地发生在HbA1c上,和(3)通过控制使糖基化主要发生在HbA1c上的病症来实现的正常血液法糖化。 这些方法产生具有期望稳定性的细胞Hb AIc对照,并且可以在各种仪器上检测。 在优选的实施方案中,对照含有完整的红细胞。
    • 10. 发明申请
    • Method of using cyanide-free lyse solution to emulate a cyanide-containing lyse solution in the measurement of hemoglobin
    • 在测量血红蛋白中使用无氰溶剂溶液来模拟含氰化物溶血溶液的方法
    • US20040048386A1
    • 2004-03-11
    • US10408827
    • 2003-04-07
    • Streck Laboratories Inc.
    • Jiong Wu
    • G01N033/72
    • G01N33/721Y10T436/105831Y10T436/25125
    • A method of emulating with a cyanide-free lyse solution, the measurement of hemoglobin in whole blood using a cyanide-containing lyse solution. Such an illustrative method includes: a) combining a predetermined amount of the whole blood sample with a predetermined amount of a cyanide-free lyse solution to form a mixture, b) developing the mixture to a molar absorbtivity (null) in the range of about 12.4 to 12.6 mMnull1cmnull1, and c) measuring a level of light absorbance of the mixture at a wavelength of about 540 nm. In one preferred illustrative embodiment, the cyanide-free lyse solution includes: a quaternary ammonium salt surfactant, an anionic surfactant, a hemoglobin binding agent selected from the group consisting of imidazole or hydroxylamine, and an aqueous medium. In one preferred embodiment, the molar absorbtivity is developed to a value of about 12.5 mMnull1cmnull1. That is to say to a level that is substantially identical to that of the prior art standard, cyanomethemoglobin. By achieving this level of molar absorbtivity, the final calculated results do not have to be corrected for the different molar absorbtivity exhibited by imidazolemethemoglobin or hydroxylaminemethemoglobin.
    • 使用不含氰化物的溶血溶液来模拟全血中的血红蛋白的方法,使用含氰化物的溶血溶液。 这样的说明性方法包括:a)将预定量的全血样品与预定量的不含氰化物的溶解溶液组合以形成混合物,b)将混合物显影至摩尔吸光度(ε)在约 12.4至12.6mM -1 cm 3,并且c)测量该混合物在约540nm波长处的吸光度。 在一个优选的说明性实施方案中,无氰化物裂解溶液包括:季铵盐表面活性剂,阴离子表面活性剂,选自咪唑或羟胺的血红蛋白结合剂和水性介质。 在一个优选的实施方案中,将摩尔吸光度显影至约12.5mM -1 cm -1的值。 也就是说,与现有技术标准,氰基血红蛋白基本相同的程度。 通过实现该摩尔吸光度的水平,最终的计算结果不必对咪唑金属红蛋白或羟基氨基血红蛋白显示的不同摩尔吸光度进行校正。